Active not recruitingOBSERVATIONAL

Definition for the Assessment of Time-to-event Endpoints in CANcer Trials (DATECAN-1)

This study, called DATECAN-1, helps cancer researchers agree on how to accurately measure important treatment effects in clinical trials. When new cancer treatments are developed, scientists need to know if they extend life or keep cancer from getting worse. Currently, different studies might use slightly different ways to measure these things, which makes it hard to compare results fairly. DATECAN-1 brings together experts to create clear, standard rules for measuring how well treatments work for various cancers like breast, pancreatic, and colon cancer, as well as sarcomas. By using the same definitions, researchers can better understand which treatments are most effective and improve future cancer care.

At a glance

Status

Active not recruiting

Sponsor

Institut Bergonié

Enrolment target

265

Start

01 Sep 2009

Estimated completion

01 Dec 2026

Cancer

Results

Results from this study

Posted February 2023

Results have been published for this study.

Primary outcome

Number of Outcomes Defined Following the Consensus Process

Number of time-to-event outcomes defined following the consensus process

Full results on the registry

What is this study about?

Imagine scientists are trying to figure out if a new cancer medicine is better than an old one. They look at things like how long people live after treatment, or how long their cancer stays under control. These are called 'endpoints'. The problem is, sometimes different studies might measure these things in slightly different ways. For example, one study might count how long a person lives from the day they start treatment, while another might count from the day their cancer was first found. When the rules for measuring are different, it's very hard to properly compare the results of different trials.

This study, DATECAN-1, aims to sort this out. It's like setting up a common rulebook for all cancer researchers. Experts from different cancer fields and research organisations come together to agree on the best and clearest ways to define these important 'endpoints'. They've looked at specific cancers such as breast cancer, pancreatic cancer, and certain types of lung cancer and sarcomas.

The goal is that once these clear rules are in place, all future cancer studies will use them. This means that when new treatments are tested, we can have much more confidence in comparing them and understanding which ones are truly making a difference for patients. Ultimately, this helps doctors and patients make better choices about treatment, leading to improved cancer care.

Key takeaways

Aiming for clearer, standard ways to measure treatment success in cancer trials.
Experts are agreeing on definitions for various cancers.
Helps compare different cancer treatments more accurately.
Not a treatment trial; patients don't receive direct interventions.
Goal is to improve future cancer research and patient care.

Who may be eligible?

This project is not a typical medical trial where patients receive new treatments. Instead, it's a research study focused on setting definitions for other clinical trials.

Therefore, there isn't an 'eligibility' for individual patients to join in the way you might think. This study involves researchers and experts who are working together to develop guidelines.

The types of cancer that these experts are focusing on include sarcoma, GIST (Gastrointestinal Stromal Tumour), breast cancer, pancreatic cancer, and a type of colon cancer that has been treated with surgery, as well as early-stage non-small cell lung cancer.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you a cancer researcher or expert in clinical trials?
Is your work related to pancreatic, breast, colon, renal cell, or early lung cancer?
Are you involved with sarcomas or GISTs?
Are you helping to develop guidelines for clinical trials?
Are you interested in standardising how cancer trial results are measured?

Answer every question to see your result.

What does participation involve?

This study is a research project designed to create guidelines for other cancer studies. It does not involve individual patients directly receiving treatments, visits, or follow-up appointments. Instead, it brings together cancer experts who discuss and agree on common definitions for measuring how well cancer treatments work. Therefore, there are no specific participation requirements for individual patients.

Potential risks and benefits

Since this study is about creating guidelines for clinical trials rather than testing new treatments on patients, there are no direct risks or benefits to individual patients. The overall benefit is for future cancer patients, as clearer guidelines will help researchers compare treatments more accurately, leading to better insights into effective therapies. This might indirectly help improve treatment options in the future.

Locations (3)

Institut Bergonié
Verified postcode
Bordeaux, France
Centre Georges François Leclerc
Verified postcode
Dijon, France
Institut du Cancer de Montpellier
Verified postcode
Montpellier, France

Common questions

What is the main goal of this DATECAN-1 study?

The main goal is to create clear, standard rules for how researchers measure important things in cancer clinical trials, like how long people live or how long their cancer stays stable.

Why are these rules important?

Having clear rules means all studies measure things in the same way. This makes it much easier to compare different treatments and truly understand which ones are most effective for patients.

Does this study involve giving patients new treatments?

No, this study does not involve giving new treatments to patients. It's a project for experts to agree on definitions for other research studies.

Which types of cancer are being looked at for these definitions?

Experts are focusing on cancers like sarcoma, GIST, breast cancer, pancreatic cancer, a type of colon cancer, and early non-small cell lung cancer.

How does this study help patients?

By making clinical trial results more reliable and easier to compare, this study ultimately helps doctors and patients make better treatment decisions in the future, improving cancer care overall.